MedPath

Gefitinib

Generic Name
Gefitinib
Brand Names
Iressa, Gefitinib Mylan
Drug Type
Small Molecule
Chemical Formula
C22H24ClFN4O3
CAS Number
184475-35-2
Unique Ingredient Identifier
S65743JHBS
Background

Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions
Metastatic Non-Small Cell Lung Cancer
Clinical Trials
Related News

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2
Not yet recruiting
Conditions
Advanced Breast Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Pancreatic Carcinoma
Advanced Prostate Carcinoma
Advanced Sarcoma
Anatomic Stage III Breast Cancer AJCC V8
Anatomic Stage IV Breast Cancer AJCC V8
Stage III Ovarian Cancer AJCC V8
Stage III Pancreatic Cancer AJCC V8
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Other: Survey Administration
First Posted Date
2024-10-08
Last Posted Date
2025-02-13
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
30
Registration Number
NCT06630325
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

Recruiting
Conditions
Pancreatic Neuroendocrine Neoplasm
Sorafenib
Gefitinib
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-01-10
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
20
Registration Number
NCT06592989
Locations
🇨🇳

Shanghai General Hospital, Shanghai, Shanghai, China

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

First Posted Date
2023-04-28
Last Posted Date
2025-03-30
Lead Sponsor
Pfizer
Target Recruit Count
5279
Registration Number
NCT05834348
Locations
🇳🇴

Pfizer Norway, Oslo, Norway

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

First Posted Date
2020-10-05
Last Posted Date
2020-10-20
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
272
Registration Number
NCT04575415
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

First Posted Date
2020-06-11
Last Posted Date
2020-06-12
Lead Sponsor
Fudan University
Target Recruit Count
120
Registration Number
NCT04425187
Locations
🇨🇳

Cancer hospital Fudan University, Shanghai, Shanghai, China

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Phase 2
Conditions
EGFR Gene Mutation
Non-small Cell Lung Cancer
Interventions
First Posted Date
2020-04-24
Last Posted Date
2020-04-24
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Target Recruit Count
240
Registration Number
NCT04358562
Locations
🇨🇳

The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3
Active, not recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Lazertinib-matching placebo 240 mg/160 mg
Drug: Gefitinib-matching placebo 250 mg
First Posted Date
2020-01-30
Last Posted Date
2024-12-03
Lead Sponsor
Yuhan Corporation
Target Recruit Count
393
Registration Number
NCT04248829
Locations
🇵🇭

Perpetual Succour Hospital, Cebu, Philippines

🇹🇭

Prince of Songkla University, Hat Yai, Thailand

🇺🇦

Tsentralna miska klinichna likarnia, Úzhgorod, Zakarpats'ka Oblast', Ukraine

and more 77 locations

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: SH-1028 tablets
Drug: Placebo SH-1028 tablets
First Posted Date
2020-01-27
Last Posted Date
2020-01-27
Lead Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Target Recruit Count
240
Registration Number
NCT04239833

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

First Posted Date
2019-11-27
Last Posted Date
2023-05-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
462
Registration Number
NCT04179890
Locations
🇬🇧

Royal Marsden Hospital, London, United Kingdom

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3
Active, not recruiting
Conditions
Locally Advanced or Metastatic NSCLC
Interventions
Drug: Placebo ASK120067
First Posted Date
2019-10-29
Last Posted Date
2024-06-14
Lead Sponsor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Target Recruit Count
337
Registration Number
NCT04143607
Locations
🇨🇳

Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

🇨🇳

Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy